PARP1 and cancer: To explore this hypothesis, we assessed the effect of the a potent and selective, clinical PRMT5 inhibitor, GSK3326595, on DNA damage response pathways and evaluated efficacy in combination with the PARP inhibitor, niraparib, in HR-proficient human cancer models.